Get the Facts

Find what you need to know
in our brochures.

DOWNLOAD

Get our
Press Kit

Official information for
articles and stories.

GET PRESS KIT

Multiple Myeloma News

Sort by Category:

Advances in Minimal Residual Disease Testing in Myeloma Meeting

On July 10 in NYC, the MMRF helped host the “Advances in Minimal Residual Disease Testing in Multiple Myeloma” meeting at Memorial Sloan Kettering Cancer Center. This meeting brought together representatives from the US Food and Drug Administration (FDA), National Cancer Institute (NCI), and the biotechnology/pharmaceutical industry, as well as key opinion leaders to discuss the latest developments around minimal residual disease (MRD) in multiple myeloma. Read More

July 30, 2015

FDA APPROVES KYPROLIS® (CARFILZOMIB) FOR COMBINATION USE IN THE TREATMENT OF PATIENTS WITH RELAPSED MULTIPLE MYELOMA

THOUSAND OAKS, Calif. (July 24, 2015) – Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for Kyprolis® (carfilzomib) for Injection in combination with Revlimid® (lenalidomide) and dexamethasone (KRd) for the treatment of patients with multiple myeloma who have received one to three prior lines of therapy. Read More

July 28, 2015

Collaborating Toward a Cure

We’ve seen how dramatically patients’ lives can change when they are matched with the right treatment at the right time in their disease course. Although this is still an exception and not the rule, we believe collaborative research approaches will make this kind of precision medicine a reality for all patients with cancers. Read More

July 28, 2015

Page 1 of 5312345...102030...Last »